@brendonneuen
Brendon Neuen
@brendonneuen
5 years
Canagliflozin, an SGLT2 inhibitor, is the first new drug approved to reduce the risk of end-stage kidney disease due to type 2 diabetes in almost 20 years. Huge news, and a great outcome for patients
U.S. FDA Approves INVOKANA® (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the...

Learn about the FDA approval of Invokana, a breakthrough in treating diabetic kidney disease and reducing heart failure risk in patients with type 2 diabetes.

www.jnj.com
2
40
107

Replies

@GlassockJ
Richard J. Glassock
@GlassockJ
5 years
@brendonneuen @EdoardoMelilli Huge! Now we will see the “real world” post-marketing experience. To call this a drug for diabetes is a big mistake- glycemic control has little to do with its beneficial effects in CKD (in Type 2DM). We shall see!!!
0
5
20
@docjv_18
💫
@docjv_18
5 years
@brendonneuen Earlier it was gliptins, that were thought to be renal protective, isnt it ?
1
0
0